Gossamer Bio, Inc., a prominent player in the biopharmaceutical sector, has recently made notable adjustments to its ownership structure, as detailed in an amendment to its Schedule 13G. This amendment, filed by Opaleye Management Inc., Opaleye, L.P., and James Silverman, reflects a change in ownership percentages that have crossed the 10% threshold, although the collective ownership remains at approximately seven percent of the company’s common shares. This figure is significant as it remains below the level that would necessitate a more detailed disclosure under Rule 13d‑1(k).
The amendment also highlights the completion of a reverse stock split, which has adjusted the number of shares outstanding. This strategic move is often employed by companies to increase the market price of their shares, potentially making them more attractive to investors. The reverse stock split, coupled with the updated ownership details, provides shareholders with a clearer view of the current ownership structure.
In addition to these changes, the amendment includes a joint filing agreement. This agreement allows the reporting persons to file a single statement on Schedule 13D or 13G for any future changes in their holdings. This streamlined approach to reporting can enhance transparency and efficiency in communication with shareholders and regulatory bodies.
Gossamer Bio, Inc., headquartered in San Diego, United States, continues to operate within the Health Care sector, specifically focusing on the biotechnology industry. The company specializes in finding, purchasing, and developing therapeutics in the disease areas of immunology, inflammation, and oncology. Since its Initial Public Offering on February 8, 2019, Gossamer Bio has served customers nationwide, maintaining a strong presence in the competitive biopharmaceutical landscape.
As of November 8, 2026, the company’s close price stood at $10.645, with a market capitalization of $59,760,000 USD. The 52-week high was recorded at $309.6 on December 14, 2025, while the 52-week low was $8.29 on October 19, 2026. The company’s price-to-earnings ratio is currently -0.19, reflecting the challenges and volatility often associated with the biotechnology sector.
Gossamer Bio’s strategic initiatives, including the recent ownership and structural adjustments, underscore its commitment to maintaining a robust and transparent operational framework. As the company continues to navigate the complexities of the biopharmaceutical industry, these developments are likely to play a crucial role in shaping its future trajectory and investor confidence.
